30 results about "Daclatasvir" patented technology

The invention provides a daclatasvir synthetic method. The method comprises the following steps: taking 4,4'-di(2-halogenated acetyl)biphenyl as a raw material, performing an esterification reaction with N-(methoxycarbonyl)-L-valine-L-proline in an organic solvent under alkali existence to obtain an intermediate B; then performing a dehydrating-cyclizing reaction on the intermediate B and ammonium acetate in an xylene solution at the temperature of 100-120 DEG C to obtain free alkali C; and reacting the free alkali C and HCl to obtain a daclatasvir crude product; and finally re-crystallizing the daclatasvir crude product to obtain daclatasvir. The synthetic method has the advantages of simple synthesis route, convenient operation and simple purifying, the purity of daclatasvir obtained by the synthesis reaction is high, the yield is large, quality of the daclatasvir bulk drug is greatly increased, production cost is reduced, and the method is suitable for large industrial production.

The invention provides a novel method for synthesizing anti-hepatitis C virus novel medicine daclatasvir. 4,4'-di(2-bromoacetyl) biphenyl serve as a raw material and first undergoes the condensation reaction with N-(methoxycarbonyl)-L-valyl-L-proline to obtain 4,4'-di(N-(methoxycarbonyl)-L-valyl-L-proline ester acetyl) biphenyl, and 4,4'-di(N-(methoxycarbonyl)-L-valyl-L-proline ester acetyl) biphenyl undergoes ring closing reaction with ammonium acetate to synthesize hepatitis C virus (HCV) NS5A inhibitor daclatasvir through two-step reaction. The novel method for synthesizing anti-hepatitis C virus novel medicine daclatasvir has the advantages that the reaction and separation and purification steps are fewer, the synthetic cycle is short and the production cost is low; and the method has wide prospect of large scale industrial application.

The invention in particular relates to a method for separating and detecting daclatasvir hydrochloride and optical isomers thereof. The method for separating and determining daclatasvir hydrochlorideand optical isomers thereof (impurities) by using liquid chromatography is characterized by comprising the following steps: adopting a chiral chromatographic column taking cellulose tris(3,5-dimethylphenylcarbamate) as a filler, and taking a mixed solution which takes sodium hexafiuorophosphate, potassium hexafluorophosphate, formic acid, acetic acid, phosphoric acid or aqueous phosphate solutionas an aqueous phase and takes acetonitrile or methanol as an organic phase as a mobile phase. According to the separating and detecting method disclosed by the invention, the daclatasvir hydrochlorideand optical isomers thereof (impurities) can be effectively separated, the degree of separation reaches 3.0 or higher, and complete baseline separation is realized, so that the quality of the daclatasvir hydrochloride can be accurately and effectively controlled. With the adoption of the separating method disclosed by the invention, the time of separating and detecting the daclatasvir hydrochloride and optical isomers thereof is within 30-80 minutes. The method disclosed by the invention has the advantages of being simple, rapid, accurate and the like.

The present invention discloses a compound and applications of the compound in preparation of anti-hepatitis C virus drugs, wherein the structure formula of the compound is represented by a formula I or II, and the compound represented by the formula I or compound represented by the formula II can be subjected to drug combination with other anti-virus drugs such as interferon (PEG IFN-[alpha]), ribavirin (RBV), boceprevir, telaprevir, simeprevir, sofosbuvir, daclatasvir and the like t prepare anti-HCV products and other anti-virus infection products. According to the present invention, the compound has rich functional group diversity and modificability, and the product is relatively easy to separate and purify; the compounds can well inhibit HCV and other viruses, are obtained through phenotype screening, have different antiviral mechanisms, have extremely novel and innovated structures in the anti-virus field, and are not reported in the prior art; and the compound of the present invention has broad development and application prospect.

The invention discloses a daclatasvir film coating tablet preparation. The preparation is prepared from the following active ingredients in percentage by mass: 12.0-20.0 percent of daclatasvir, 2.0-8.0 percent of a disintegrating agent, 50.0-80.0 percent of a diluting agent and 0.5-1.5 percent of a lubricating agent, wherein the disintegrating agent is one or more of croscarmellose sodium, hydroxypropyl methylcellulose and sodium carboxymethyl starch, one or two of sodium carboxymethylcellulose and hydroxypropyl methylcellulose as first choice, and preferably sodium carboxymethylcellulose; the diluting agent is one or more of microcrystalline cellulose, lactose anhydrous, mannitol and polyethylene glycol, one or two of microcrystalline cellulose and mannitol as first choice, and preferably microcrystalline cellulose; and the lubricating agent is one or more of magnesium stearate, talcum powder, aerosil and calcium stearate, one or two of magnesium stearate and aerosil, and preferably magnesium stearate. The daclatasvir film coating tablet preparation has the advantages of simple process, high yield, good stability and the like, and is easy for large-scale industrial production.

The invention provides a preparation method of a deuterated daclatasvir intermediate, and particularly relates to a preparation method of N-(trideuteromethoxycarbonyl)-L-valine. According to the preparation method, the intermediate is obtained through two-step synthesis by taking CDI as an activating reagent. Compared with a triphosgene route in the prior art, the route has the advantages that the yield and the utilization rate of deuterated methanol can be improved, and meanwhile, the pollution to the environment is greatly reduced.

The present application relates to the amorphous form of Daclatasvir dihydrochloride and the processes for the preparation thereof. The application further provides its solid dispersion having Daclatasvir dihydrochloride in amorphous form and process for its preparation.

The invention relates to the technical field of biochemical engineering and specifically relates to an industrial production method for a Daclatasvir key intermediate 5,5'-[1,1'-biphenyl]-4,4'-diyl di[2-(2S)-2-pyrrolidyl-1H-imidazole]terthydrochloride. The 5,5'-[1,1'-biphenyl]-4,4'-diyl di[2-(2S)-2-pyrrolidyl-1H-imidazole]terthydrochloride is prepared according to a one-pot method. Compared with aconventional process, the industrial production method for the Daclatasvir key intermediate 5,5'-[1,1'-biphenyl]-4,4'-diyl di[2-(2S)-2-pyrrolidyl-1H-imidazole]terthydrochloride is capable of efficiently and stably producing high-quality 5,5'-[1,1'-biphenyl]-4,4'-diyl di[2-(2S)-2-pyrrolidyl-1H-imidazole]terthydrochloride, the purity of the intermediate is greater than 99%, and the content of unknown single impurities is smaller than 0.3%.

The invention provides a method for preparing daclatasvir and belongs to the field of pharmaceutical and chemical industry. According to the method, a compound shown in a formula II and a compound shown in a formula III are subjected to a condensation reaction, a mixture A is obtained, alkali is added, the mixture is stirred at a certain temperature, so that the mixture A reacts, an organic solvent is added for extraction and liquid separation after the reaction ends, an organic phase is concentrated and dried, and daclatasvir is obtained. The method has the characteristics that the product produced with the method has high purity, the method is high in yield, low in cost and simple to operate and the process is stable.

The invention provides a method for preparing a compound shown in formula I. The method comprises the steps as follows: a compound shown in formula II is contacted with a compound shown in formula III, so that the compound shown in formula I is obtained, wherein X1 is Cl, Br, I, trifluoromethanesulfonic acid and enol phosphate; R is alkyl, hydroxyl or alkoxy. The compound shown in the formula is an intermediate DSV103 of daclatasvir. The method for preparing the intermediate DSV103 has the characteristics of being high in purity, high in yield, low in cost, simple to operate, small in toxicityand pollution and stable in process, the yield can reach 60%-80%, and the purity can reach 95% or above. Daclatasvir can be further obtained from the daclatasvir intermediate obtained with the preparation process, and the obtained daclatasvir has higher purity and yield than the prior art.

The invention discloses a high performance liquid chromatography and chiral mobile phase separated hydrochloric acid daclatasvir and five optical isomers thereof. The high performance liquid chromatography and chiral mobile phase separated hydrochloric acid daclatasvir is characterized in that L-asparaginic acid, (2R, 3R)-dipropyl tartaric acid, D-(+)-Di-p-toluoyl-L-tartaric acid, (1R, 2R)-(-)-N-(p-methylphenylsulfonyl)-1, 2-diphenylethanediamine or L-valyl-L-tyrosine is used as an additive and added to the mobile phase, and a common C18 liquid chromatographic column can be utilized to effectively separate hydrochloric acid daclatasvir and five optical isomers thereof, and mutual baseline separation is achieved. The technicians in the field know that the chiral mobile phase is limited andcan only be used for separating limited compounds, and systemic theory guidance is not provided to guide any compound to be separated through the chiral mobile phase, and the chiral mobile phase for separating is only performed by 'trial and error' repeated testing and random exploring. Therefore, the method is not obvious to the technicians in the field and has the creativity as specified by thepatent law.

The invention provides a method for preparing Daclatasvir. According to the method disclosed by the invention, N-(methoxycarbonyl)-L-valine and 5,5'-(4,4'-biphenylyl)di(2-((2S)-2- pyrrolidinyl)-1hydrogen-imidazole)tetrahydrochloride are used as reaction materials, under the participation of an activating agent namely 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride and an alkaline reagent, ethyl cyanoglyoxylate-2-oxime is used as a reaction catalyst, and a reaction is performed in an alcohol solvent. The method for preparing the Daclatasvir provided by the invention is simple and convenient to operate, economic and cheap, environmental-friendly, safe, high in recovery rate and suitable for industrialized production.

The invention discloses a quantitative detection method of daclatasvir in beagle plasma, and belongs to the technical field of drug detection. The quantitative detection method comprises the followingsteps of: 1) preparing a daclatasvir series working solution and a daclatasvir-d6 internal standard working solution; 2) pretreating to-be-detected beagle plasma; 3) preparing a series of calibrationstandard samples and accompanying quality control samples; and (4) measuring the concentration of the daclatasvir in the to-be-measured beagle plasma, wherein a standard curve is drawn by taking a chromatographic peak area ratio of the daclatasvir to the internal standard daclatasvir-d6 as a vertical coordinate and taking the concentration of the daclatasvir in the beagle blank plasma as a horizontal coordinate, and the concentration of the daclatasvir in the to-be-measured beagle plasma is calculated according to the standard curve. According to the quantitative detection method, a protein precipitation method is adopted to treat a beagle plasma sample, an electrospray ion source is used as an ionization technology, the detection method is simple and convenient to operate, high in sensitivity, good in reproducibility, high in selectivity, low in detection limit, short in analysis time and suitable for high-throughput quantitative determination of the beagle plasma sample and preclinical beagle in-vivo pharmacokinetic research.

The invention discloses a one-pot preparation technology of an NS5A protein inhibitor daclatasvir. The technology mainly comprises the following three steps: 1) preparing an intermediate DT1: carryingout a butt reaction on reaction initial raw materials which are DTM1, DTM2 and DTM3 under the action of an alkali reagent and a condensing agent to prepare the intermediate DT1; 2) preparing an intermediate DT2: cyclizing the intermediate DT1 and an amine compound to prepare the intermediate DT2; and 3) preparing daclatasvir: removing an amino protecting group from the intermediate DT2 by using an amino protecting group removing reagent to prepare the product daclatasvir. The method for preparing daclatasvir has the characteristics of high product yield, simple and easy-to-operate overall process, no strong corrosive substances in the preparation materials, effectiveness in safety ensuring, and suitableness for large-scale industrial production.

The present invention relates to a continuous micro-electro-flow reactor system for ultra-fast, oxidant free, C—C coupling reaction for making symmetrical biaryls and analogs thereof. This invention further relates to the said process for preparation of antiviral drug, daclatasvir of general formula I.

The invention discloses a high performance liquid chromatography chiral mobile phase method for separation of daclatasvir hydrochloride and five optical isomers thereof. The daclatasvir hydrochlorideand the five optical isomers thereof can be effectively separated by adding of L-aspartic acid, (2R, 3R) bis-n-propyl tartaric acid, (+)-di-p-toluoyl-D-tartaric acid, and (1R, 2R)-(-)-N-(p-toluenesulfonyl)-1,2-diphenylethylenediamine or L-valyl-L-tyrosine as additives to a mobile phase by use of a common C18 liquid chromatography column, and baseline resolution of every two of the daclatasvir hydrochloride and the five optical isomers thereof can be achieved. Persons skilled in the art know that a chiral mobile phase method is very limited in that and only a limited number of compounds can beseparated, no systematic theory can guide which compounds can be separated by the chiral mobile phase method, and only a trial-and-error method can be used for repeatedly trying and groping without rules. Accordingly, the high performance liquid chromatography chiral mobile phase method has obvious creativity prescribed by the patent law for the persons skilled in the art.